KBR, Inc. (NYSE:KBR) is one of billionaire Leon Cooperman’s top stock picks with huge upside potential. Late in May, KBR, Inc. (NYSE:KBR) declared that the U.S. Navy Facilities Engineering Systems ...

Lightweight, accurate and impressively specified, Mark Camoccio tests the new Kral Puncher K to see if it hits the mark ...

Advancements in Genomics and AI Propel Patient-Centric Therapies Across Key Regions The global personalized medicine market is experiencing accelerated growth as a result of the increasing prevalence ...

SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating ...

As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 in six cohorts (Capsules: 2mg, 4mg, 8mg, 15mg, 22mg / Tablets: 4mg). The ...

NEW YORK--(BUSINESS WIRE)--May 30, 2025-- ...

BRAF mutations are estimated to occur in 8-12% of people with mCRC and represent a poor prognosis for these patients. 2 The BRAF V600E mutation is the most common BRAF mutation and the risk of ...

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European ...

Immunotherapy-based regimens consisting of a PD-1 inhibitor with or without a CTLA-4 inhibitor or a LAG-3 inhibitor, as well as targeted therapy consisting of the combination of BRAF and MEK ...

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...